Ovagen vs Pal-GHK
Side-by-side comparison of key properties, dosing, and research.
- Summary
- Ovagen is a tripeptide bioregulator (Glu-Asp-Leu) developed by Professor Vladimir Khavinson, primarily targeting liver tissue. It supports hepatocyte function, liver cell regeneration, and protection against hepatic aging and disease. Ovagen is used in protocols for chronic liver disease, hepatoprotection, and metabolic liver conditions including fatty liver disease.
- Pal-GHK is the palmitoylated form of the GHK tripeptide without a copper ion. By conjugating palmitic acid to glycine-histidine-lysine, skin penetration is substantially enhanced, enabling deeper dermal collagen stimulation. It is commonly paired with Pal-GHK-Cu or GHK-Cu in anti-aging formulations.
- Half-Life
- Short (minutes); sustained gene-regulatory effects
- Extended (lipid depot in stratum corneum)
- Admin Route
- SubQ, Oral
- Topical
- Research
- —
- —
- Typical Dose
- 10 mg per day
- 0.005–0.1% in formulation
- Frequency
- Daily for 10–30 days
- Once or twice daily
- Key Benefits
- Hepatoprotective effects against toxic, viral, and metabolic liver damage
- Promotes hepatocyte regeneration and liver tissue repair
- May reduce liver fibrosis progression
- Supports liver metabolic function and detoxification capacity
- Anti-aging effects on hepatic tissue
- Useful in NAFLD/MASH supportive protocols
- Compatible with NAD+, glutathione, and BPC-157 in liver health stacks
- Stimulates collagen I and III synthesis in dermis
- Reduces the appearance of fine lines and wrinkles
- Improves skin elasticity and firmness
- Inhibits collagenase (MMP-1) to preserve existing collagen
- Enhances wound healing and skin repair
- Well-tolerated in anti-aging serums and creams
- Side Effects
- Generally well tolerated
- Mild injection site reactions
- No clinically significant hepatotoxicity reported
- Generally very well-tolerated
- Rare skin irritation at very high concentrations
- Possible formulation-dependent comedogenicity
- Stacks With
- —
- —